Tender Details

Country: USA
Summary: PLUVICTOâ„¢ (lutetium Lu 177 vipivotide tetraxetan) Prostate Cancer Therapy (NDC Code: 69488-0010-61) VA Palo Alto Health care System
UST Ref No: 120328450
Deadline: 10 Jun 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 36C26126Q0002
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
Special NoticeSpecial NoticePage 3 of 3*= Required FieldPage 1 of 3This notice is published IAW Federal Acquisition Regulation (FAR) Subpart 5.101 requiring posting of information for proposed contract actions. The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 21 intends to award a sole source firm-fixed price contract to Novartis Pharmaceuticals Corporation under the authority of FAR 8.405-6(a)(1)(B), Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. VA Palo Alto Healthcare System Nuclear Medicine Department has a requirement for Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan), a radioactive therapy treatment for Prostate-specific Membrane Antigen-Positive Metastatic Castration-Resistant Prostate Cancer (PSMA-Positive mCRPC).If your firm provides the radiopharmaceutical therapy on GSA Federal Supply Schedule or any Federal Supply Schedule, please provide applicable contract number and identify which supply/service are applicable to that FSS contract, and the following additional information (1) A tailored capability statement indicating the firm s ability to provide a product and related services; (2) The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc.,) pursuant to the applicable NAICS code; (3) Information should be provided electronically in a Microsoft Word or Adobe PDF format. Potential offerors must be a manufacturer or fully licensed, authorized distributor for the radiopharmaceutical items. Potential offerors must be FDA certified.This ...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

PLUVICTOâ„¢ (lutetium Lu 177 vipivotide tetraxetan) Prostate Cancer Therapy (NDC Code: 69488-0010-61) VA Palo Alto Health care System - USA Tender

The VETERANS AFFAIRS, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for PLUVICTOâ„¢ (lutetium Lu 177 vipivotide tetraxetan) Prostate Cancer Therapy (NDC Code: 69488-0010-61) VA Palo Alto Health care System. This tender is published on USARFP under UST Ref No: 120328450 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-06-10.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.